Fortrea Holdings Inc.

$ 15.31 -0.07 %

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

CEO: Anshul Thakral - https://www.fortrea.com

Price objectif

$18.17 18.68 %

Recommandation

Hold

DCF

$ -19.60

Loading data...

FTRE vs S&P500

Loading data...

No data available.

Quick ratio

0.95

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

-3.19

may indicate that the company is undervalued or has poor growth prospects.

EPS

-4.80

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-79.12 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-0.83 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

11.18

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

2.13

means it relies more on debt, which can increase financial risk.

Free cash flow per share

2.09

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
0.21 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.16 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.42 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.